Longeveron shares rise 11.11% premarket after Phase 2 trial reveals laromestrocel reduces hippocampal neuroinflammation in Alzheimer’s.

Longeveron Inc. (NASDAQ: LGVN) rose 11.11% in premarket trading following the release of new MRI biomarker data from its Phase 2 CLEAR-MIND trial, showing laromestrocel reduced neuroinflammation in key Alzheimer’s disease (AD)-associated brain regions, including the hippocampus. The findings, presented at the CTAD 2025 conference, demonstrated a durable anti-inflammatory effect of the stem cell therapy, with reductions in free water fraction—a marker of neuroinflammation—across multiple regions compared to placebo. The results reinforced laromestrocel’s proposed mechanism of action in addressing AD pathology and highlighted clinical benefits, including preserved hippocampal volume and improved outcomes. The therapy has already received RMAT and Fast Track designations from the FDA, bolstering its regulatory pathway. The positive data likely drove investor optimism about the treatment’s potential to address unmet needs in mild AD, directly correlating with the sharp premarket price increase.